Healthy
Conditions
Keywords
microbiota, breast milk, diet
Brief summary
MAMI aims to characterize maternal microbes to be transferred to neonates and determine their function in infant health programming.
Detailed description
Recent reports suggest that early microbial colonization has an important role for in promoting health. This may contribute to reduce the risk of chronic diseases such as obesity, allergies and inflammatory conditions. Advances in understanding host-microbe interactions imply that maternal microbiota plays a crucial role on health programming. This process begins in utero and it is modulated by mode of delivery and diet. The investigator's previous data has shown that i) specific shifts in milk microbial composition are associated with lactation time and mode of delivery, ii) milk microbes drive the infant microbiota composition; iii) maternal microbiota dysbiosis may be transferred to the infant. However, factors defining maternal microbiota and its biological role upon infant's health are not yet fully understood. Hence, this project aims to characterize maternal microbes to be transferred to neonates and determine their function in infant health programming. The specific aims are:(1) understanding how the maternal microbiome is influenced by host and environmental factors;(2) characterizing the microbial core and bioactive compounds transmitted to the offspring mainly via breastfeeding and their key roles in the microbial modulation and host response;(3) understanding the interactions among breast milk bioactive compounds and their role in infant health;(4) shedding light on how maternal microbes influence the infant immune system. Results obtained will demonstrate the interaction between infant nutrition, microbes and host response in early life and its key role in health programming, enabling new applications in the field of personalized nutrition & medicine.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* Age\> 18 years. * Healthy woman (no medication, no diabetes, no pre-gestational thyroid problems) * Postpartum woman (beginning of the puerperium).
Exclusion criteria
* Non-compliance with any of the inclusion criteria. * Medication and drugs * Health problems at the immunological and metabolic levels.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Microbiota composition | from birth to 24 month | Dominant microbial species maternal and infant samples (using qPCR and sequencing -approaches analysis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maternal BMI | pre-gestational | To check Body Mass Index (kg/cm2) |
| Maternal weight | pre-gestational and from birth to 12 months post-partum | To check Weight gain over pregnancy (kg) and weight during lactation |
| To identify maternal factors affecting microbiota: antibiotics | pre-gestational | antibiotics treatment during gestation (number of treatments) |
| To identify the impact of mode of delivery | Birth | Mode of delivery type: Vaginal/C-section (elective or non-elective) |
| Maternal diet | from birth to12 month | Maternal diet (FFQ) during gestation and 12 month post-partum |
| Infant height | from birth to 24 month | Infant height (cm) |
| Infant Diet | from bith to 24 month | Exclusive breastfeeding time (months), breastfeeding duration and time of introduction of complementary food |
| Fecal short-chain fatty acids | from birth to 24 month | Determine the relationship between fecal microbiota composition and fecal short chain fatty acids |
| Infant weight | from birth to 24 month | Infant weight (kg) |
Countries
Spain